Eytan M. Stein

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum et al. · Blood · 2022 · 3K citations · Full text

Medicine, Hematology, Oncology +17

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea et al. · Blood · 2017 · 1.5K citations · Full text

Medicine, Hematology, Oncology +13

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio et al. · Nature · 2023 · 468 citations · Full text

Medicine, Molecular Biology, Oncology +13

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Eytan M. Stein, Guillermo Garcia‐Manero, David A. Rizzieri et al. · Blood · 2018 · 457 citations · Full text

Life Sciences, Molecular Biology, Oncology +10